Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
about
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionA New Scientific Paradigm may be Needed to Finally Develop an HIV VaccineThe evolution of poxvirus vaccinesHead-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman PrimatesTargeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques.Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved AntigensDeletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-SpeciVaccine vectors based on Adenovirus 19a/64 exhibit broad cellular tropism and potently restimulate HCMV-specific T cell responses ex vivo.
P2860
Q26775082-4DFFD227-3FD7-4628-B777-D3862852B6A6Q26830360-2EAC5D9D-50DC-4F50-BD0E-E4F7C5828467Q26995905-B1127EC7-3087-4D80-8ABC-90833D473946Q35914311-FFD10C4E-8827-46AF-B40C-1F2A8F4F52ABQ35989484-CB48CB95-09E1-4E19-A10F-6A023F1FAA02Q36736400-F3C85C83-2764-471D-9717-2E6D7F09E7EAQ36947039-7D2B2C4F-25E6-4310-8CAE-928949D6C416Q40220988-8CA6BE51-F593-4B39-9F56-D2E2B3189804Q40339467-F4817E49-530A-407A-9568-01AC951675DBQ47549105-75D9E1F5-A3D2-40BA-B7A0-7FE1446BB50A
P2860
Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Virological and immunological ...... clade C trimeric soluble gp140
@nl
Virological and immunological ...... CN54) as virus-like particles.
@ast
Virological and immunological ...... CN54) as virus-like particles.
@en
type
label
Virological and immunological ...... clade C trimeric soluble gp140
@nl
Virological and immunological ...... CN54) as virus-like particles.
@ast
Virological and immunological ...... CN54) as virus-like particles.
@en
prefLabel
Virological and immunological ...... clade C trimeric soluble gp140
@nl
Virological and immunological ...... CN54) as virus-like particles.
@ast
Virological and immunological ...... CN54) as virus-like particles.
@en
P2093
P2860
P50
P356
P1433
P1476
Virological and immunological ...... (CN54) as virus-like particles
@en
P2093
Beatriz Perdiguero
Benedikt Asbach
Bertram L Jacobs
Carlos Óscar S Sorzano
Cristina Sánchez
Ernesto Mejías-Pérez
Julie Delaloye
Karen V Kibler
Lucas Sánchez-Sampedro
Ralf Wagner
P2860
P304
P356
10.1128/JVI.02469-14
P407
P50
P577
2014-10-29T00:00:00Z